fMRI Evaluation of Parkinson's Disease

帕金森病的功能磁共振成像评估

• 批准号: 6833909
• 负责人: CATHERINE L ELSINGER
• 金额: $ 10万
• 依托单位: NEUROGNOSTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-20 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6833909
• 关键词: Parkinson' s disease; antiparkinson drugs; bioimaging /biomedical imaging; biomarker; clinical research; computer program /software; diagnosis design /evaluation; diagnosis quality /standard; dopamine; drug screening /evaluation; functional magnetic resonance imaging; human old age (65+); human subject; neuropharmacology; pharmacokinetics; therapy design /development

DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a progressive and incurable neurological disease affecting an estimated 4 million people worldwide. Health care costs in the U.S. alone have been estimated in excess of $6B. While many FDA-approved therapeutic interventions (pharmaceutical, surgical and physiological) have become available for the management of the motor and cognitive complications associated with PD, the majority of interventions become less effective over time as the disease progresses. The challenge is to develop more effective and longer lasting treatments that alter the disease course in addition to managing symptoms. Identifying incremental therapeutic efficacy over existing treatments may be hindered by existing clinical outcome measures that suffer from relatively low reliability and sensitivity. The next wave of clinical trials, therefore, will likely require reliable and sensitive biological markers that correlate with clinical outcomes. In Phase I of this project, we propose to test the efficacy of functional magnetic resonance imaging (fMRI), as a biomarker for quantifying a therapeutic response in PD. Phase II will entail the development of a standardized neuroimaging platform based on proprietary technology to be implemented across wide range of MRI scanner platforms. This commercial platform will target academic medical centers, hospitals, and clinics, as well as the pharmaceutical industry, in order to facilitate the evaluation of therapeutic response in PD.

描述（由申请人提供）：帕金森氏病（PD）是一种进步且无法治愈的神经系统疾病，影响了全球估计有400万人。仅美国的医疗保健费用估计超过$ 6B。尽管许多经FDA批准的治疗干预措施（药物，外科和生理学）已用于管理运动和与PD相关的运动并发症的管理，但随着疾病进展，大多数干预措施随着时间的流逝而变得较低。面临的挑战是开发更有效，更持久的治疗方法，除了管理症状外，还可以改变疾病病程。 识别对现有治疗的增量治疗功效可能会受到遭受相对较低的可靠性和敏感性的现有临床结果指标的阻碍。因此，下一波临床试验可能需要与临床结局相关的可靠和敏感的生物学标记。在该项目的第一阶段，我们建议测试功能磁共振成像（fMRI）的功效，作为量化PD治疗反应的生物标志物。第二阶段将需要开发基于专有技术的标准化神经影像平台，该平台将在广泛的MRI扫描仪平台上实施。这个商业平台将针对学术医疗中心，医院和诊所以及制药行业，以促进PD中治疗反应的评估。